Related Experiment Video

Updated: Jul 16, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

Increased tau protein differentiates mild cognitive impairment from geriatric depression and predicts conversion to

Peter Schönknecht1, Johannes Pantel, Elmar Kaiser

  • 1Section of Geriatric Psychiatry, University of Heidelberg, Heidelberg, Germany.

Neuroscience Letters
|March 3, 2007
PubMed

Insights

Cerebrospinal fluid (CSF) total tau (t-tau) and phosphorylated tau (p-tau) can help differentiate mild cognitive impairment (MCI) from depression. Higher baseline t-tau and p-tau levels in MCI patients predict progression to Alzheimer's disease (AD).

Area of Science:

  • Neurology
  • Biochemistry
  • Geriatrics

Background:

  • Mild cognitive impairment (MCI) diagnosis is challenging due to overlap with geriatric major depressive disorder.
  • Alzheimer's disease (AD) progression is a significant concern for MCI patients.
  • Current diagnostic tools lack specific biomarkers for differentiating MCI from depression and predicting AD conversion.

Purpose of the Study:

  • To investigate cerebrospinal fluid (CSF) total tau (t-tau) and phosphorylated tau (p-tau) as differential diagnostic markers.
  • To assess the prognostic value of CSF t-tau and p-tau levels in predicting conversion from MCI to AD.
  • To explore CSF tau biomarkers for distinguishing geriatric major depressive disorder from MCI.

Main Methods:

  • CSF t-tau and p-tau levels were measured using ELISA in 80 MCI subjects, 54 major depression patients, and 24 healthy controls.
  • Participants were followed for at least 12 months to track clinical progression.
  • Baseline biomarker levels were compared between groups and correlated with conversion to AD.

Main Results:

  • MCI patients who converted to AD (29%) showed significantly higher baseline CSF t-tau and p-tau levels compared to non-converters.
  • Elevated t-tau and p-tau levels were observed in MCI patients compared to healthy controls and major depression patients.
  • Only one patient with major depression converted to AD during the follow-up period.

Conclusions:

  • CSF t-tau and p-tau levels are valuable biomarkers for the differential diagnosis between MCI and geriatric major depressive disorder.
  • Elevated CSF t-tau and p-tau levels at baseline have prognostic value, indicating an increased risk of progression to Alzheimer's disease in MCI patients.

More Related Videos

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...